Muscular Dystrophy

Muscular dystrophy is a group of inherited genetic disorders that cause progressive damage and weakness in the muscles. There are more than 30 types, and they differ in the age at which symptoms begin, the muscles affected, the rate of progression, and the complications they may cause. Some forms, such as Duchenne muscular dystrophy, usually begin in early childhood, while others, including myotonic and facioscapulohumeral muscular dystrophy, may not become apparent until adolescence or adulthood.

Although there is currently no cure for muscular dystrophy, treatment and supportive care have advanced considerably. Early diagnosis, appropriate medication, physical therapy, and regular monitoring of heart and respiratory function can help people maintain mobility, manage complications, and protect their health. The care plan depends on the specific type of muscular dystrophy and the needs of each person.

What Is Muscular Dystrophy?

Muscular dystrophy refers to a group of genetic conditions in which muscle fibers gradually become damaged, leading to progressive muscle weakness and, in some cases, loss of muscle tissue. The underlying gene changes affect proteins that help muscle cells maintain their structure and function. When these proteins are missing, reduced, or abnormal, muscle fibers become more vulnerable to damage during normal movement and activity.

A Group of Genetic Muscle Disorders

More than 30 forms of muscular dystrophy have been identified. Although progressive muscle weakness is a shared feature, the conditions are not interchangeable. Each type is associated with particular genetic changes and tends to affect specific muscle groups, although the pattern and severity can vary even among people with the same diagnosis.

Some forms primarily affect the muscles around the hips and shoulders, while others involve the face, neck, hands, or lower legs. Certain types also affect the heart, breathing muscles, or other organs. Age at onset ranges from before birth or infancy to adulthood, and some forms progress much more slowly than others.

Identifying the exact type is therefore essential. It helps doctors anticipate possible complications, select appropriate treatments, arrange the right monitoring schedule, and provide more accurate information about inheritance and family planning.

How Muscular Dystrophy Differs From Other Muscle and Nerve Disorders

Muscular dystrophy is a primary muscle disorder caused by inherited genetic changes. Other conditions can also cause weakness or movement difficulties, but they affect different parts of the neuromuscular system.

• Spinal muscular atrophy (SMA): A genetic condition that affects motor nerve cells in the spinal cord, leading to muscle weakness and wasting. It is not a type of muscular dystrophy.

• Amyotrophic lateral sclerosis (ALS): A progressive motor neuron disease that damages the nerve cells controlling voluntary muscles.

• Myasthenia gravis: An autoimmune disorder affecting communication between nerves and muscles, causing weakness that often becomes more pronounced with activity.

• Inflammatory myopathies: A group of acquired muscle diseases in which inflammation damages muscle tissue. Unlike muscular dystrophy, they are not generally caused by inherited changes in muscle-related genes.

Distinguishing these conditions matters because their causes, diagnostic tests, treatments, and expected progression are different.

Types of Muscular Dystrophy

The types of muscular dystrophy are classified according to the genetic change, inheritance pattern, age at onset, and distribution of muscle weakness. Some forms primarily affect children, while others may first cause symptoms in adults. The following table summarizes several major types and their typical features; individual experiences can differ.

Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is one of the most common and severe childhood-onset forms. It mainly affects boys and usually becomes apparent before the age of five. DMD is caused by changes in the dystrophin gene, which provides instructions for making dystrophin, a protein that helps protect muscle fibers from damage during contraction.

Without sufficient functional dystrophin, muscle fibers are progressively damaged and replaced by fat and connective tissue. Weakness often begins in the hips, thighs, and pelvic muscles, then affects the upper body, arms, and respiratory muscles. Heart muscle involvement can also develop, making regular cardiac monitoring an essential part of care.

Children with DMD may have difficulty running, climbing stairs, standing up from the floor, or keeping up with other children. The condition usually progresses over time, but corticosteroids, cardiac treatment, respiratory support, and rehabilitation have improved disease management and survival.

Becker Muscular Dystrophy

Becker muscular dystrophy (BMD) is also caused by changes in the dystrophin gene, but the body usually produces some functional dystrophin. This generally results in a milder and more variable course than Duchenne muscular dystrophy.

Symptoms may begin during childhood, adolescence, or adulthood. Weakness commonly affects the hips and thighs, and some people experience calf enlargement, muscle cramps, or difficulty with physical activity. The rate of progression varies considerably, and some people remain mobile well into adulthood.

Heart involvement is an important concern in Becker muscular dystrophy and may sometimes occur even when skeletal muscle symptoms are mild. Regular cardiac assessment is therefore important regardless of the degree of visible muscle weakness.

Myotonic Dystrophy

Myotonic dystrophy is the most common adult-onset form of muscular dystrophy, although symptoms can also begin in childhood or at birth. It is an inherited condition that affects muscle relaxation as well as muscle strength. Myotonia refers to difficulty relaxing a muscle after it has contracted, such as trouble releasing an object after gripping it.

Two main forms are recognized: myotonic dystrophy type 1 (DM1) and type 2 (DM2). DM1 commonly affects the face, neck, hands, and lower legs, while DM2 often involves the neck, shoulders, hips, and upper legs. The severity and combination of symptoms vary.

Myotonic dystrophy can affect more than skeletal muscles. Cataracts, heart rhythm abnormalities, breathing problems, digestive difficulties, and hormonal changes may occur. Because the condition can involve several body systems, assessment and follow-up should extend beyond muscle strength.

Facioscapulohumeral Muscular Dystrophy

Facioscapulohumeral muscular dystrophy (FSHD) primarily affects the muscles of the face, shoulder blades, and upper arms. The name describes these areas: facio refers to the face, scapulo to the shoulder blades, and humeral to the upper arms.

Symptoms often begin in adolescence or early adulthood, although childhood-onset cases occur. People may have difficulty closing their eyes tightly, smiling, whistling, or raising their arms above shoulder level. Weakness may affect one side of the body more than the other, and some people develop weakness in the abdominal muscles or lower legs.

FSHD usually progresses slowly, but the degree of muscle involvement varies. Most people do not develop the same pattern of heart and respiratory complications seen in some other types, although assessment should be guided by symptoms and the specific clinical presentation.

Limb-Girdle Muscular Dystrophy

Limb-girdle muscular dystrophy (LGMD) describes a group of genetic disorders that primarily affect the muscles around the hips and shoulders. The term limb-girdle refers to the pelvic and shoulder areas, where the limbs connect to the trunk.

LGMD can begin in childhood, adolescence, or adulthood. Common signs include difficulty climbing stairs, getting up from a chair, lifting objects overhead, or rising from the floor. Some genetic subtypes progress slowly, while others cause more rapid weakness or involve the heart and respiratory muscles.

There are many genetic subtypes of LGMD, and they do not all follow the same inheritance pattern or clinical course. Genetic testing helps identify the specific subtype and determine which complications require monitoring.

Congenital Muscular Dystrophy

Congenital muscular dystrophy (CMD) refers to forms that are present at birth or become apparent during infancy. Babies may have low muscle tone, delayed motor development, joint contractures, or difficulty feeding and breathing. The severity ranges from relatively mild weakness to significant early involvement of multiple body systems.

Some congenital forms primarily affect skeletal muscles, while others may also involve the brain, eyes, spine, or respiratory system. The underlying genetic subtype is important because it influences the expected course and the assessments needed during childhood.

Other Types of Muscular Dystrophy

Several less common forms have distinctive patterns of muscle involvement:

• Emery-Dreifuss muscular dystrophy: Often begins in childhood or adolescence and is associated with muscle contractures, weakness in the upper arms and lower legs, and potentially serious heart rhythm or conduction problems.

• Oculopharyngeal muscular dystrophy: Usually begins in adulthood and commonly causes drooping eyelids and difficulty swallowing.

• Distal muscular dystrophy: A group of disorders that primarily affect muscles in the hands, forearms, feet, or lower legs. Onset and progression depend on the genetic subtype.

Symptoms of Muscular Dystrophy

Progressive muscle weakness is the main feature shared by muscular dystrophy types, but the first affected muscles and the age at which symptoms appear vary. In children, early signs may involve delayed motor milestones or difficulty with activities such as running and climbing stairs. In adults, weakness may develop gradually and initially affect specific muscle groups, making it easier to overlook.

Early Signs in Children

The early signs of muscular dystrophy depend on the type. In Duchenne muscular dystrophy, symptoms often become noticeable in the preschool years, while congenital forms may cause weakness from birth. Parents may first notice that a child has difficulty keeping up with peers or performing movements that require strength in the hips and legs.

Common signs include:

• Delayed motor milestones: A child may begin walking later than expected or have difficulty developing age-appropriate movement skills.

• Frequent falls: Weakness in the hip and thigh muscles can make running, jumping, and walking less stable.

• Difficulty climbing stairs: A child may need to hold a railing, use their hands to pull themselves upward, or avoid stairs.

• Waddling gait or walking on the toes: Changes in walking pattern may develop as weakness affects the hips and lower legs.

• Enlarged calf muscles: Some children with Duchenne muscular dystrophy develop calf pseudohypertrophy, in which muscle tissue is partly replaced by fat and connective tissue, making the calves appear larger.

• Gowers sign: A child may use their hands to push against their thighs while standing up from the floor because the hip and thigh muscles are weak.

A child who loses previously acquired motor skills or shows persistent, unexplained weakness should be evaluated by a healthcare professional.

Symptoms in Teens and Adults

Adult-onset muscular dystrophy may develop gradually, and symptoms depend on the type. People with Becker or limb-girdle muscular dystrophy may notice difficulty walking uphill, climbing stairs, or lifting their arms. In facioscapulohumeral muscular dystrophy, weakness of the facial and shoulder muscles may be more noticeable than weakness in the legs.

Myotonic dystrophy can cause muscle stiffness after contraction, hand weakness, and difficulty relaxing the grip. Drooping eyelids and swallowing difficulties may occur in myotonic or oculopharyngeal muscular dystrophy. Some people experience muscle pain or fatigue, although these symptoms are not specific to muscular dystrophy.

Heart, Breathing, and Other Effects

Muscular dystrophy can affect more than the muscles used for movement. Depending on the type, complications may involve the heart, respiratory system, spine, joints, and other organs.

• Heart problems: Cardiomyopathy, a condition in which the heart muscle becomes weakened or enlarged, can develop in Duchenne, Becker, and some limb-girdle and myotonic forms. Heart rhythm and electrical conduction abnormalities may also occur.

• Breathing difficulties: Weakness in the diaphragm and other respiratory muscles can reduce the ability to take deep breaths or cough effectively. Some people develop sleep-related breathing problems before noticing daytime symptoms.

• Scoliosis and contractures: Weakness and muscle imbalance may contribute to spinal curvature. A contracture occurs when muscles, tendons, or surrounding tissues become shortened, restricting joint movement.

• Swallowing and feeding difficulties: Some types affect the muscles involved in chewing and swallowing, increasing the risk of choking or aspiration.

• Learning and behavioral differences: Certain forms, particularly Duchenne and some congenital types, may be associated with learning, attention, or developmental differences. These do not occur in every person.

Regular heart and respiratory assessments are important even when symptoms are not obvious, because complications may develop before a person notices a change.

When to See a Doctor

A medical assessment is recommended when a child has delayed motor development, frequent unexplained falls, difficulty climbing stairs, or loss of previously acquired movement skills. Adults should seek evaluation for progressive muscle weakness, unexplained changes in walking, difficulty swallowing, or a family history of muscular dystrophy.

Worsening breathlessness, fainting, chest pain, or sudden changes in heart rhythm require urgent medical attention. These symptoms should not be attributed to muscular dystrophy without prompt assessment, as they may indicate serious cardiac or respiratory complications.

What Causes Muscular Dystrophy? Genetics and Inheritance

Muscular dystrophy is caused by genetic changes that interfere with proteins needed for normal muscle structure and function. These changes may be inherited from one or both parents, depending on the type, or may arise for the first time in the affected person. The specific gene involved determines the form of muscular dystrophy and helps explain why symptoms and inheritance patterns differ.

Gene Changes and Dystrophin

Dystrophin is a protein that helps stabilize muscle fibers during contraction and movement. It acts as part of a support system connecting the internal structure of a muscle cell to surrounding tissues. When dystrophin is absent or significantly reduced, muscle fibers become more vulnerable to damage and gradually break down.

Duchenne and Becker muscular dystrophy are both caused by changes in the DMD gene, which is located on the X chromosome. In Duchenne muscular dystrophy, the genetic change usually prevents the body from producing functional dystrophin. In Becker muscular dystrophy, some dystrophin is generally produced, although it may be reduced or abnormal.

Other forms involve different genes and proteins. For example, the genetic changes responsible for limb-girdle, myotonic, and facioscapulohumeral muscular dystrophy affect different processes involved in maintaining muscle function.

Inheritance Patterns

Muscular dystrophy can follow several inheritance patterns:

• X-linked inheritance: Duchenne and Becker muscular dystrophy are usually inherited through changes in the DMD gene on the X chromosome. Boys have one X chromosome, so a disease-causing change in that copy can cause the condition. Girls and women with one altered copy are often carriers, although some develop muscle weakness or heart problems.

• Autosomal dominant inheritance: One altered copy of a gene is enough to cause the condition. Myotonic and many cases of facioscapulohumeral muscular dystrophy follow this pattern. A person with the condition may have a 50% chance of passing the altered gene to each child.

• Autosomal recessive inheritance: A person must inherit an altered copy of the relevant gene from both parents to develop the condition. Many limb-girdle muscular dystrophy subtypes follow this pattern. Parents who each carry one altered copy are generally unaffected but can pass the change to their children.

Not every case is inherited from an affected parent. Some people, particularly those with Duchenne muscular dystrophy, have a new genetic change that was not present in the family history.

Carriers and Genetic Counseling

A carrier has a genetic change associated with a condition but may not develop the same symptoms as someone with two affected gene copies or a disease-causing change in a single X chromosome. Female carriers of Duchenne or Becker muscular dystrophy may have no noticeable symptoms, but some develop muscle weakness or heart involvement and need appropriate assessment.

Genetic counseling can help individuals and families understand test results, inheritance patterns, and the likelihood of passing a genetic change to future children. Depending on the family situation, testing may be offered to relatives, and reproductive options can be discussed without pressure toward any particular decision.

How Is Muscular Dystrophy Diagnosed?

Muscular dystrophy diagnosis involves identifying the pattern of muscle weakness and determining whether an inherited genetic change is responsible. The evaluation usually begins with a review of symptoms, family history, and physical examination. Blood tests, genetic testing, and other investigations may then be used to confirm the diagnosis and identify the specific type.

Examination and Blood Tests

The doctor assesses muscle strength, movement, reflexes, posture, walking pattern, and the ability to perform tasks such as standing up from a chair or climbing a step. In children, the evaluation may also consider developmental milestones and whether motor skills have been delayed or lost.

A creatine kinase (CK) blood test is commonly used when muscular dystrophy is suspected. Creatine kinase is an enzyme found in muscle cells. When muscle fibers are damaged, CK can enter the bloodstream, causing elevated levels. CK is often markedly raised in Duchenne muscular dystrophy, although levels vary across types and may be less elevated in some adult-onset forms. An elevated result alone does not establish a diagnosis.

Genetic Testing

Genetic testing is central to confirming most forms of muscular dystrophy. A blood or saliva sample can be analyzed for changes in genes associated with the suspected condition. Identifying the specific genetic change helps establish the subtype, clarify inheritance, guide family counseling, and determine whether a person may be eligible for certain targeted treatments or clinical trials.

If initial testing does not identify a disease-causing change, a specialist may recommend broader genetic analysis or additional investigations, depending on the clinical findings.

EMG, Muscle MRI, and Muscle Biopsy

Other tests can help distinguish muscular dystrophy from nerve disorders and acquired muscle conditions or clarify which muscles are affected.

• Electromyography (EMG): Records electrical activity in muscles and can help determine whether weakness is caused by a muscle disorder or a nerve problem. It may be used alongside nerve conduction studies as part of the diagnostic assessment.

• Muscle MRI: Shows the distribution of muscle involvement and can help identify patterns associated with particular muscular dystrophy types.

• Muscle biopsy: In selected cases, a small muscle sample is examined under a microscope to assess muscle structure and the presence or absence of specific proteins. Genetic testing has reduced the need for biopsy in many patients, but it may still be useful when the diagnosis remains unclear.

For more information about the examination, see the guide to electromyography (EMG).

Heart and Lung Assessment

Because several types of muscular dystrophy can affect the heart and respiratory muscles, evaluation should include appropriate cardiac and breathing tests. An electrocardiogram (ECG) records the heart's electrical activity, while an echocardiogram uses ultrasound to assess heart structure and pumping function. Cardiac MRI or rhythm monitoring may be recommended in some cases.

Respiratory assessment may include lung function tests, measurement of breathing strength, and evaluation of cough effectiveness. Sleep studies may be considered when symptoms suggest sleep-related breathing problems. The type and frequency of monitoring depend on the diagnosis, age, symptoms, and previous test results.

Muscular Dystrophy Treatment

There is currently no cure for muscular dystrophy, and treatment cannot reliably reverse established muscle damage. However, care can help slow or manage aspects of disease progression, maintain mobility, protect heart and lung function, and address complications. Treatment is tailored to the specific type and usually involves several medical specialties rather than a single intervention.

Medications

Medication options depend on the type of muscular dystrophy and the complications a person develops. In Duchenne muscular dystrophy, corticosteroids such as prednisone or deflazacort are commonly used to help preserve muscle strength and function and delay some aspects of disease progression. Long-term use requires monitoring for side effects, which may include weight gain, changes in behavior, reduced bone density, growth effects, and increased risk of infection.

Some medications target specific genetic changes in Duchenne muscular dystrophy. Exon-skipping drugs are designed for people whose particular DMD gene mutation can be addressed by skipping a selected section of genetic code. This may allow the body to produce a shorter form of dystrophin. These treatments apply only to certain genetic variants and do not benefit everyone with Duchenne muscular dystrophy.

Givinostat, a histone deacetylase inhibitor, is another medication approved for Duchenne muscular dystrophy in some countries. Vamorolone, a corticosteroid-related treatment, is also approved in certain regions. Eligibility, safety monitoring, age restrictions, and availability vary by country and may change as regulatory authorities review new evidence.

Heart medications, including medicines used to manage cardiomyopathy and heart failure, may be prescribed when cardiac involvement is identified. Treatment decisions should be based on the specific diagnosis and regular assessments rather than waiting for symptoms to become severe.

Gene Therapy and Clinical Trials

Gene therapy for Duchenne muscular dystrophy aims to deliver genetic instructions that allow muscle cells to produce a shortened version of dystrophin, known as micro-dystrophin. It is not a cure, and it is not suitable for every person with the condition.

In the United States, the FDA has approved delandistrogene moxeparvovec (Elevidys) for a restricted group of ambulatory patients aged four years and older with a confirmed DMD gene mutation. Its indication and safety information have changed following reports of serious and fatal liver injury, and the FDA added a boxed warning. Treatment requires careful assessment and intensive monitoring. Approval in one country does not mean the therapy is approved or available in Turkey or elsewhere.

Clinical trials are also investigating new approaches to muscular dystrophy, including gene-based treatments, medications, and other strategies to preserve muscle function. People interested in participating should discuss eligibility, potential risks, and expected benefits with a neuromuscular specialist. Trial information can be reviewed through ClinicalTrials.gov, but registration does not mean that a study is recruiting or that participation is appropriate for every patient.

Physical Therapy, Mobility Aids, and Orthopedic Care

Physical therapy helps maintain joint movement, manage stiffness, and support daily function. A physiotherapist can recommend individualized stretching, positioning, and low-impact activities while avoiding exercise that places excessive strain on weakened muscles. The program should be adapted to the person's muscular dystrophy type, strength, and stage of progression.

Braces, splints, and other orthotic devices may help support joints, maintain positioning, or improve walking. As mobility changes, canes, walkers, manual wheelchairs, or powered mobility devices can help people remain active and participate in daily life. These aids should be selected according to individual needs rather than delayed until mobility becomes severely limited.

Orthopedic care may be needed for joint contractures, foot deformities, or scoliosis. In Duchenne muscular dystrophy, spinal curvature may become more pronounced as muscle weakness progresses, particularly after loss of independent walking. Treatment decisions depend on the degree of curvature, respiratory function, and overall health.

Heart and Breathing Care

Regular cardiac monitoring is important in Duchenne and Becker muscular dystrophy and in other types known to affect the heart. Cardiologists may recommend preventive or therapeutic medication when changes in heart function are detected. ECG, echocardiography, cardiac MRI, and rhythm monitoring may be used at intervals determined by the patient's condition.

Respiratory care focuses on identifying reduced breathing strength before serious complications develop. Depending on the findings, management may include breathing exercises, assisted coughing techniques, airway clearance, or noninvasive ventilation, particularly during sleep. Respiratory infections should be assessed promptly because weakened breathing muscles can make it harder to clear mucus and recover from illness.

Nutrition, Bone Health, and Emotional Support

A balanced diet can support general health, maintain an appropriate body weight, and help reduce additional strain on muscles and joints. Nutritional needs may change as mobility decreases or swallowing difficulties develop. A dietitian can help address weight management, adequate protein and nutrient intake, and safe food textures when needed.

Bone health also requires attention, particularly in people with Duchenne muscular dystrophy who take long-term corticosteroids or have reduced mobility. Monitoring may include assessment of vitamin D status, bone density, and fracture risk. Psychological support, school accommodations, and access to patient and family resources can also help address the practical and emotional challenges of living with a progressive condition.

Surgery and Anesthesia Precautions

Muscular dystrophy can increase the risk of complications during and after surgery. People with Duchenne or Becker muscular dystrophy may have serious reactions to certain anesthetic drugs, particularly succinylcholine, which can trigger severe muscle breakdown, dangerous potassium levels, and potentially life-threatening heart complications. Some inhaled anesthetic agents may also pose risks in these conditions.

Anyone diagnosed with muscular dystrophy should tell the surgeon and anesthesiologist about the condition before any operation, procedure, or sedation. The anesthesia team needs to review the specific diagnosis, heart and respiratory function, medications, and previous anesthetic history to plan appropriate care and monitoring. These precautions are important even when the planned procedure is not directly related to muscular dystrophy.

Unproven Treatments and Stem Cell Claims

People searching for muscular dystrophy treatment may encounter clinics advertising stem cell therapy or other regenerative treatments as a cure. These claims should be approached with caution. Stem cell treatments have not been established as a cure for muscular dystrophy, and unproven interventions may carry medical risks, substantial costs, and no reliable evidence of lasting benefit.

Before considering an experimental treatment, patients and families should ask whether it has been evaluated in properly designed clinical trials, whether it has regulatory approval for the specific diagnosis, and what published evidence supports its safety and effectiveness. A neuromuscular specialist can help distinguish established care from experimental approaches and misleading treatment claims.

Muscular Dystrophy Life Expectancy and Outlook

Muscular dystrophy life expectancy varies widely according to the type, genetic subtype, age at onset, rate of progression, and involvement of the heart and respiratory muscles. Some people with milder forms, including certain cases of facioscapulohumeral or limb-girdle muscular dystrophy, may have a near-normal lifespan. Other forms can cause significant complications earlier in life and require more intensive long-term care.

Duchenne muscular dystrophy has historically been associated with shortened life expectancy, but survival has improved as corticosteroid treatment, cardiac medication, respiratory support, and coordinated specialist care have advanced. Outcomes still vary considerably, and no single life expectancy figure can accurately describe every person with DMD. Heart and respiratory monitoring are particularly important because complications involving these systems have a major influence on long-term health.

The outlook for Becker muscular dystrophy, myotonic dystrophy, congenital muscular dystrophy, and other forms also depends on the specific subtype and complications. A genetic diagnosis and regular clinical assessments allow the care team to identify risks earlier and adapt treatment as needs change. The aim is not only to extend life but also to preserve function, independence, comfort, and participation in everyday activities.

Living With Muscular Dystrophy

Living with muscular dystrophy may involve changes in mobility, school or work routines, and daily activities, but the condition does not define a person's abilities or quality of life. Support should reflect individual goals and changing needs, with practical adjustments that help people remain involved in education, employment, relationships, and community life.

Children may benefit from coordinated support between families, healthcare professionals, and schools. Depending on their needs, accommodations can include accessible classrooms, additional time to move between lessons, adapted physical education, and support with fatigue or mobility. As young people approach adulthood, planning the transition from pediatric to adult neuromuscular care helps maintain continuity in cardiac, respiratory, and rehabilitation follow-up.

Adults may need adjustments at home or work as muscle weakness progresses. Occupational therapists can recommend ways to conserve energy, adapt daily tasks, and improve accessibility. Physical activity should be tailored to the diagnosis and individual capacity; strenuous exercise that causes excessive fatigue or muscle damage should be avoided.

Patient organizations and support groups can provide practical information, opportunities to connect with other families, and guidance on education, equipment, and care resources. Regular communication with the healthcare team also helps address new symptoms and adjust the care plan over time.

Multidisciplinary Neuromuscular Care at Medical Park

Muscular dystrophy requires long-term care that addresses more than muscle weakness. At Medical Park hospitals in Turkey, the evaluation of suspected neuromuscular disorders can begin with a neurological assessment of muscle strength, movement, reflexes, medical history, and family history. Depending on the clinical findings, investigations such as creatine kinase testing, genetic testing, electromyography (EMG), and muscle imaging may be considered to help identify the specific condition and guide further evaluation.

Care planning depends on the type of muscular dystrophy and the organs involved. Neurology specialists assess the neuromuscular condition and coordinate the diagnostic approach, while Cardiology specialists evaluate and monitor possible heart involvement. When respiratory muscles are affected, Pulmonology assessment can help identify breathing difficulties and determine whether respiratory support is needed. Physical Therapy and Rehabilitation specialists can address mobility, muscle function, joint movement, and rehabilitation needs as the condition changes. The investigations and services available depend on the patient's clinical requirements and the selected hospital.

Medical Park’s International Patient Services Center helps international patients and their families coordinate consultations, diagnostic appointments, treatment planning, and follow-up arrangements in Turkey. This support can help patients organize assessments across specialties and understand the next steps recommended by their care team.